Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.
about
Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical ImplicationsHCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral TherapyNew era for management of chronic hepatitis C virus using direct antiviral agents: A reviewDrug-drug interactions during antiviral therapy for chronic hepatitis CDaclatasvir: potential role in hepatitis CDaclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysisA quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivityRational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus InfectionNS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection.Daclatasvir: A Review in Chronic Hepatitis C.Pharmacokinetics of new oral hepatitis C antiviral drugs.Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration.Novel permissive cell lines for complete propagation of hepatitis C virus.The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C.Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents.In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.Inherent structural disorder and dimerisation of murine norovirus NS1-2 protein.Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.Hepatitis C virus NS5A inhibitors and drug resistance mutations.Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 InfectionDirect-acting antivirals for chronic hepatitis C.In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone.An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjectsResistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevirGenetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance.Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvirHepatitis C viral kinetics: the past, present, and future.Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation.Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan.Anti-HCV drugs in the pipeline.Echocardiogram study to evaluate the effect of the novel hepatitis C virus NS5A inhibitor GSK2336805 on cardiac contractility in healthy subjects.Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1Approaches to hepatitis C treatment and cure using NS5A inhibitorsFuture therapies for chronic hepatitis C.Interferon-free regimens for hepatitis C: combine and conquer.
P2860
Q26777408-1A6522B7-097A-4ADD-A504-9F6CAC2A1276Q26782405-E58377AB-611B-4623-A9B0-CD72FB089ABFQ26800050-9C3AECAF-46A3-455A-B6FE-FF022D7C37B3Q26864887-A06616FE-FEAB-40D7-A599-4D00F4CCF835Q27012741-2D4EB380-E92C-47F3-97E0-1192CDCB56F7Q28073108-75FE396C-27A4-44CB-932D-01E6011D2D8BQ28537708-DF371B72-56C2-4316-ABC9-11C781A81033Q28545971-B63ED5B5-658C-4102-9B6C-47A98C113658Q30352718-63C86B96-2D59-4552-9BAD-15D3CA4EDDBCQ30392100-68D58313-AD91-4E67-A4FE-5EEBD2F27126Q30422746-5F2666C3-E2F0-4D58-B36D-4302C4E0BD83Q30685690-2DD5C155-2B33-4240-AFD7-055226F4800BQ33602824-910F184B-3D18-4F39-9C96-DDFC1D1CF4DBQ33621649-EF46CB0C-89E9-46D1-A583-BCF228DB1F57Q33622970-C6BDF363-7CAD-4974-AB7B-92EAF354D023Q34057584-19ED5974-7F79-46DD-BB53-92146C6BB89DQ34058093-F736598A-9B89-4A50-B053-B699164F3CCBQ34162531-98BBEE8A-FE13-4FD4-A43B-A59B90219260Q34332546-3EA13C40-F3ED-42ED-89F9-73D658F97B76Q34411617-CDBCF2D3-9496-4720-A2AB-9B06FD6B6EFFQ34506788-F365BDB9-0BF7-4EC2-8C71-5820FB3B4FBEQ34557595-6A354C44-8046-4DD8-9567-0B7D7B13A9C3Q34634693-07118E3C-850A-4C22-B7ED-D36B25B3FE06Q34634791-01DA2BF8-A266-49FC-95E4-CE80F0D02D02Q35960681-4D5FCFE1-46E0-480C-A3CF-72A22663F020Q35980958-F4617A71-FD45-46A2-A700-A7E0F0937CB3Q36086454-B8EF8819-9E7F-4BB1-A765-A5CAEF35DF42Q36096436-30D27F7A-C143-4D26-BC37-BA79FE27D628Q36276803-ABB8DB73-52BD-4671-A950-F1165875241EQ36645517-F0C57946-FAD8-4C3A-AEB2-E8DBBA3EAFA1Q36724391-10758A8D-5DFD-4250-8D46-C6E73031D9F3Q36785846-3AEF845A-9667-4390-9934-FBD72FA267F2Q36816846-83E62804-725B-4866-A894-B5E25E5C9B68Q36997093-9F4ED433-7223-4269-B133-9549E432D249Q37177740-64615605-6330-477E-BC2A-00800621AAF9Q37263769-73BAACD7-0DCB-47A2-AC06-DCFF69657379Q37263870-D98A2A70-D686-496E-AFC9-A64266EDA53EQ37630422-DF5B18DA-68D7-4EA8-AFD7-8968C9257714Q38082566-27694D15-8AA3-4392-851A-25E8C66AFDEDQ38156403-84B37F16-25CC-464B-9AC2-4170A83B38BD
P2860
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Multiple ascending dose study ...... hepatitis C virus genotype 1.
@en
Multiple ascending dose study ...... hepatitis C virus genotype 1.
@nl
type
label
Multiple ascending dose study ...... hepatitis C virus genotype 1.
@en
Multiple ascending dose study ...... hepatitis C virus genotype 1.
@nl
prefLabel
Multiple ascending dose study ...... hepatitis C virus genotype 1.
@en
Multiple ascending dose study ...... hepatitis C virus genotype 1.
@nl
P2093
P2860
P356
P1433
P1476
Multiple ascending dose study ...... hepatitis C virus genotype 1.
@en
P2093
Anna Persson
Apinya Vutikullird
Dennis M Grasela
Ellen Chung
Eric Lawitz
Ernesto Fuentes
Juan Carlos Lopez-Talavera
Marc Bifano
Maribel Rodriguez-Torres
Michael P DeMicco
P2860
P304
P356
10.1002/HEP.24609
P407
P577
2011-12-01T00:00:00Z